Karo Bio Quarterly Report January-March 2004

QUARTERLY REPORT jANUARY-MARCH 2004 * Substantial progress has been made in the collaboration with Wyeth Pharmaceuticals in the discovery of lead compounds that show significant anti atherogenic effects in animal disease models. * The internal STAD dyslipidemia project continues to make good progress and two patent applications have been filed for selected compounds. * New and more potent androgen antagonists have been designed in the prostate cancer project and a patent application has been filed for selected compounds. * Net sales amounted to MSEK 10.1 (12.7). * The loss for the period, including goodwill expenses, decreased to MSEK 34.2 (100.4). Operating loss excluding goodwill expenses decreased to MSEK 35.1 (42.0). * Cash flows from operating activities amounted to MSEK -36.1 (-39.7). Cash and cash equivalents and short-term investments amounted to MSEK 148.9 (161.2) at the end of the period. * Loss per share for the period amounted to SEK 2.03 (7.82). For further information, please contact Björn O. Nilsson, President & CEO tel. +46 8 608 60 20, Bertil Jungmar, Chief Financial Officer, tel. +46 8 608 60 52. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/04/23/20040423BIT00020/wkr0001.doc The full report http://www.waymaker.net/bitonline/2004/04/23/20040423BIT00020/wkr0002.pdf The full report